<!DOCTYPE html>
<html>
    <head>
        <title>ONALABS QMS : OV Part G: Clinical Evaluation, PMS and PMCF</title>
        <link rel="stylesheet" href="styles/site.css" type="text/css" />
        <META http-equiv="Content-Type" content="text/html; charset=UTF-8">
    </head>

    <body class="theme-default aui-theme-default">
        <div id="page">
            <div id="main" class="aui-page-panel">
                <div id="main-header">
                    <div id="breadcrumb-section">
                        <ol id="breadcrumbs">
                            <li class="first">
                                <span><a href="index.html">ONALABS QMS</a></span>
                            </li>
                                                    <li>
                                <span><a href="OV-ONAVITAL-MDR-Product-Technical-File_3342337.html">OV ONAVITAL MDR Product Technical File</a></span>
                            </li>
                                                </ol>
                    </div>
                    <h1 id="title-heading" class="pagetitle">
                                                <span id="title-text">
                            ONALABS QMS : OV Part G: Clinical Evaluation, PMS and PMCF
                        </span>
                    </h1>
                </div>

                <div id="content" class="view">
                    <div class="page-metadata">
                            
        
    
        
    
        
        
            Created by <span class='author'> Richard Bunney</span>, last modified by <span class='editor'> Jaime Punter</span> on May 20, 2025
                        </div>
                    <div id="main-content" class="wiki-content group">
                    <p><span class="status-macro aui-lozenge aui-lozenge-visual-refresh aui-lozenge-error">COMPANY CONFIDENTIAL</span> <span class="status-macro aui-lozenge aui-lozenge-visual-refresh aui-lozenge-error">UNCONTROLLED IF PRINTED</span></p><p>Owner: Jaime Punter, CTO and Quality Representative</p><div class="ap-container" id="ap-com.automation-consultants.accloud.approvalmacro__ApprovalsStatusMacro6151109740783652116">

  <div class="ap-content " id="embedded-com.automation-consultants.accloud.approvalmacro__ApprovalsStatusMacro6151109740783652116"></div>
  <script nonce="528a568c4bd9f0fff5a3a25050ba0fb5" class="ap-iframe-body-script">
  (function(){
    var data = {
    "addon_key":"com.automation-consultants.accloud.approvalmacro",
    "uniqueKey":"com.automation-consultants.accloud.approvalmacro__ApprovalsStatusMacro6151109740783652116",
    "key":"ApprovalsStatusMacro",
     "moduleType":"dynamicContentMacros",      "moduleLocation":"content",         "cp":"/wiki",
            "general":"",
    "w":"",
    "h":"",
    "url":"https://ac-cloud.com/approvalmacro/macro/page-status/display?xdm_e=https%3A%2F%2Fonalabs.atlassian.net&xdm_c=channel-com.automation-consultants.accloud.approvalmacro__ApprovalsStatusMacro6151109740783652116&cp=%2Fwiki&xdm_deprecated_addon_key_do_not_use=com.automation-consultants.accloud.approvalmacro&lic=active&cv=1000.0.0-c58bc7260813&traceId=d4ffc4fcae7882811e0c4f1a08058586&spanId=fe44acb18feb6d3b&traceSampled=0&jwt=eyJ0eXAiOiJKV1QiLCJhbGciOiJIUzI1NiJ9.eyJzdWIiOiI2MDU0OTY2Yjk0ZDdiOTAwNjkwMmRkMWUiLCJxc2giOiIxMjFhNjFhZjhhYjNlMDYwZjFkOWVlMWM1ZGQ5ZjA3ZTQzODk5Mzg2M2I0OGM3NjY0Zjk4ZmY2NWM2MGEzOGU4IiwiaXNzIjoiNzdjODA3YTAtMmNjNy0zZWVjLWEzNDItOWQzYzYyZjUwZWE0IiwiY29udGV4dCI6e30sImV4cCI6MTc1MTI5NjM5NSwiaWF0IjoxNzUxMjk2MjE1fQ.4xSWRl40JvNUDGxIWsCRtfnfYrldyHOA47ZIdtQ2B6E",
     "contextJwt": "eyJ0eXAiOiJKV1QiLCJhbGciOiJIUzI1NiJ9.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.0g8V4zxRX3EW7NVB_0jsVvUH91fDGgTSlu0VdImNYaU",    "structuredContext": "{\"license\":{\"active\":true},\"confluence\":{\"editor\":{\"version\":\"v2\"},\"macro\":{\"outputType\":\"html_export\",\"hash\":\"82652211-bf23-4643-83d9-ec7b8106aba8\",\"id\":\"82652211-bf23-4643-83d9-ec7b8106aba8\"},\"tracing\":{\"traceId\":\"d4ffc4fcae7882811e0c4f1a08058586\",\"spanId\":\"fe44acb18feb6d3b\",\"sampled\":\"0\"},\"content\":{\"type\":\"page\",\"version\":\"7\",\"id\":\"3343001\"},\"space\":{\"key\":\"ONALABSQMS\",\"id\":\"2752512\"}},\"url\":{\"displayUrl\":\"https://onalabs.atlassian.net/wiki\"}}",
    "contentClassifier":"content",
    "productCtx":"{\"page.id\":\"3343001\",\"macro.hash\":\"82652211-bf23-4643-83d9-ec7b8106aba8\",\"space.key\":\"ONALABSQMS\",\"tracing.sampled\":\"0\",\"page.type\":\"page\",\"content.version\":\"7\",\"page.title\":\"OV Part G: Clinical Evaluation, PMS and PMCF\",\"macro.localId\":\"d4b3b57b-6977-4535-ba47-dae6eec4ffb6\",\"macro.body\":\"\",\": = | RAW | = :\":null,\"space.id\":\"2752512\",\"macro.truncated\":\"false\",\"content.type\":\"page\",\"output.type\":\"html_export\",\"page.version\":\"7\",\"macro.fragmentLocalId\":\"\",\"content.id\":\"3343001\",\"tracing.traceId\":\"d4ffc4fcae7882811e0c4f1a08058586\",\"macro.id\":\"82652211-bf23-4643-83d9-ec7b8106aba8\",\"tracing.spanId\":\"fe44acb18feb6d3b\",\"user.isExternalCollaborator\":\"false\",\"editor.version\":\"v2\"}",
    "timeZone":"GB",
    "origin":"https://ac-cloud.com",
    "hostOrigin":"https://onalabs.atlassian.net",
    "sandbox":"allow-downloads allow-forms allow-modals allow-popups allow-popups-to-escape-sandbox allow-scripts allow-same-origin allow-top-navigation-by-user-activation allow-storage-access-by-user-activation",    "pearApp":"true",        "apiMigrations": {
        "gdpr": true
    }
}
;
    if(window.AP && window.AP.subCreate) {
      window._AP.appendConnectAddon(data);
    } else {
      require(['ac/create'], function(create){
        create.appendConnectAddon(data);
      });
    }

    // For Confluence App Analytics. This code works in conjunction with CFE's ConnectSupport.js.
    // Here, we add a listener to the initial HTML page that stores events if the ConnectSupport component
    // has not mounted yet. In CFE, we process the missed event data and disable this initial listener.
    const __MAX_EVENT_ARRAY_SIZE__ = 20;
    const connectAppAnalytics = "ecosystem.confluence.connect.analytics";
    window.connectHost && window.connectHost.onIframeEstablished((eventData) => {
      if (!window.__CONFLUENCE_CONNECT_SUPPORT_LOADED__) {
        let events = JSON.parse(window.localStorage.getItem(connectAppAnalytics)) || [];
        if (events.length >= __MAX_EVENT_ARRAY_SIZE__) {
          events.shift();
        }
        events.push(eventData);
        window.localStorage.setItem(connectAppAnalytics, JSON.stringify(events));
      }
    });

  }());
</script>

</div>
<ul><li><p><a class="external-link" href="https://tinnisoothe.atlassian.net/wiki/spaces/TF/pages/3833857/Device+Version+History#1.-Purpose" rel="nofollow">1. Purpose</a></p></li><li><p><a class="external-link" href="https://tinnisoothe.atlassian.net/wiki/spaces/TF/pages/3833857/Device+Version+History#2.-Version-History" rel="nofollow">2. Version History</a></p></li><li><p><a class="external-link" href="https://tinnisoothe.atlassian.net/wiki/spaces/TF/pages/3833857/Device+Version+History#3.-Document-Distribution" rel="nofollow">3. Document Distribution</a></p></li></ul><h3 id="OVPartG:ClinicalEvaluation,PMSandPMCF-1.Purpose">1. Purpose</h3><p>To record and maintain a record of the clinical evaluation of the medical device and post market surveillance activity in accordance with regulation (EU) 2017/745 of the European Parliament and of the Council.</p><h3 id="OVPartG:ClinicalEvaluation,PMSandPMCF-2.DesignandManufacturingInformation">2. Design and Manufacturing Information</h3><div class="table-wrap"><table data-layout="wide" data-local-id="27414e48-784a-4975-9f81-a7fad940f932" class="confluenceTable"><colgroup><col style="width: 229.0px;"/><col style="width: 384.0px;"/><col style="width: 364.0px;"/></colgroup><tbody><tr><td data-highlight-colour="#ffa9a4" class="confluenceTd"><p><strong>Section Title / Item</strong></p></td><td data-highlight-colour="#ffa9a4" class="confluenceTd"><p><strong>Additional Guidance</strong></p></td><td data-highlight-colour="#ffa9a4" class="confluenceTd"><p><strong>Details</strong></p></td></tr><tr><td data-highlight-colour="#b3f5ff" colspan="3" class="confluenceTd"><p><strong>6.6 Clinical Evaluation</strong></p></td></tr><tr><td class="confluenceTd"><p><strong>6.6.1 Clinical development strategy</strong></p></td><td class="confluenceTd"><p><strong>E</strong>xplain the clinical development strategy for the device.</p></td><td class="confluenceTd"><p>See <a href="OV-G1.1.-Clinical-Evaluation-Plan_3343029.html" data-linked-resource-id="3343029" data-linked-resource-version="78" data-linked-resource-type="page">OV G1.1. Clinical Evaluation Plan</a> </p><p>Complete</p></td></tr><tr><td class="confluenceTd"><p><strong>6.6.2 Clinical development plan</strong></p></td><td class="confluenceTd"><p><strong> </strong>See MDR Annex XIV, Part A, 1 (a) final indent.</p><p>a clinical development plan indicating progression from exploratory investigations, such as first-in-man studies, feasibility and pilot studies, to confirmatory investigations, such as pivotal clinical investigations, and a PMCF as referred to in Part B of this Annex with an indication of milestones and a description of potential acceptance criteria;</p></td><td class="confluenceTd"><p>See <a href="OV-G1.1.-Clinical-Evaluation-Plan_3343029.html" data-linked-resource-id="3343029" data-linked-resource-version="78" data-linked-resource-type="page">OV G1.1. Clinical Evaluation Plan</a> </p><p>Complete</p></td></tr><tr><td class="confluenceTd"><p><strong>6.6.3 Clinical evaluation plan</strong></p></td><td class="confluenceTd"><p>Please provide the clinical evaluation plan documented and used for the device.</p></td><td class="confluenceTd"><p>See <a href="OV-G1.1.-Clinical-Evaluation-Plan_3343029.html" data-linked-resource-id="3343029" data-linked-resource-version="78" data-linked-resource-type="page">OV G1.1. Clinical Evaluation Plan</a> </p></td></tr><tr><td class="confluenceTd"><p><strong>6.6.4 Clinical evaluation report</strong></p></td><td class="confluenceTd"><p>Clinical evaluations are required for all medical devices.</p><p>Representative clinical data must be provided for all indications and variants. Justifications for why one group of data is representative of another must be clearly substantiated.</p><p>If no clinical investigation data are available for the subject device and the Clinical Evaluation relies on a justification of equivalence of comparative devices, the justification must identify and discuss the potential clinical impact of all differences between the subject and comparable devices relative to intended use, technical, or biological factors (MDR Annex XIV Sec. 3). In the context of equivalence, Manufacturers should also include any additional information necessary to show compliance with the requirements of MDR Article 61.5 for implantable devices and Class III devices.</p><p>If the device is a system with multiple components, the clinical evaluation must consider all the components of the device. Similarly, the clinical evaluation must give due consideration to the accessories associated with the device.</p></td><td class="confluenceTd"><p>See <a href="OV-G1.2.1-Clinical-Evaluation-Report-ONAVITAL-Prototype_49446913.html" data-linked-resource-id="49446913" data-linked-resource-version="12" data-linked-resource-type="page">OV G1.2.1 Clinical Evaluation Report ONAVITAL Prototype</a> </p><p>Complete</p></td></tr><tr><td class="confluenceTd"><p><strong> 6.6.5 CVs of the relevant personnel associated with the Clinical evaluation report to establish appropriate competence</strong></p></td><td class="confluenceTd"><p><strong> </strong>A justification should be provided (with appropriate evidence) to substantiate the qualifications of individual(s) conducting / approving the clinical evaluation.</p></td><td class="confluenceTd"><p>See <a href="OV-G1.1.-Clinical-Evaluation-Plan_3343029.html" data-linked-resource-id="3343029" data-linked-resource-version="78" data-linked-resource-type="page">OV G1.1. Clinical Evaluation Plan</a> complete</p></td></tr><tr><td class="confluenceTd"><p><strong> 6.6.6 Clinical investigation protocols</strong></p></td><td class="confluenceTd"><p>For devices without suitable equivalents and / or insufficient data in the literature, pre-market clinical investigation may be required.</p><p>In addition, for Class III devices and Class IIb implantable devices, pre- market clinical investigation will be required unless:</p><p>·     The device is demonstrated to be equivalent to another of the manufacturer’s own devices with sufficient clinical data available demonstrating conformity with the relevant GSPRs</p><p>·     The device is demonstrated to be equivalent to an already marketed device of another manufacturer and a contract is in place explicitly allowing ongoing access to that manufacturer’s Technical Documentation</p><p>·     For listed device types where the clinical evaluation is based on sufficient data and in compliance with relevant CS</p><p>·     The device had been lawfully placed on the market or put into service per Directives 90/385/EEC or 93/42/EEC, where the clinical evaluation is based on sufficient clinical data and is in compliance with any relevant CS;</p><p>·     Annex XIV and XV describe Clinical Evaluation and Clinical Investigations, respectively. Guidance is also available in EN-ISO 14155 Clinical investigation of medical devices for human subjects - Good clinical practice</p><p>If a pre-market clinical investigation has been conducted, please ensure:</p><p>·     appropriate documentation (CIP, letter of “no objection” from the Competent Authority, evidence of Ethics approval, final report, etc.) is provided;</p><p>·     the final clinical trial protocol agrees with that submitted to the Competent Authority, and evidence that any deviations have been agreed with the CA has been provided;</p><p>·     the final report demonstrates that requirements for all safety and performance endpoints have been met;</p><p>·     there are no open clinical investigations relevant to your devices with endpoints related to safety or performance claims.</p></td><td class="confluenceTd"><p>See <a href="OV-G1.2.1-Clinical-Evaluation-Report-ONAVITAL-Prototype_49446913.html" data-linked-resource-id="49446913" data-linked-resource-version="12" data-linked-resource-type="page">OV G1.2.1 Clinical Evaluation Report ONAVITAL Prototype</a> </p></td></tr><tr><td class="confluenceTd"><p><strong> </strong></p><p><strong>6.6.7 Clinical investigation results</strong></p></td><td class="confluenceTd"><p>If a pre-market clinical investigation has been conducted, please ensure:</p><p>·     the final report demonstrates that requirements for all safety and performance endpoints have been met;</p><p>·     there are no open clinical investigations relevant to your devices with endpoints related to safety or performance claims.</p><p><strong> </strong>See also 6.6.6</p></td><td class="confluenceTd"><p>Incomplete - to add. Summary format should match new guidance  </p><p><a class="external-link" data-card-appearance="inline" href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52023XC0508(01)" rel="nofollow">https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52023XC0508(01)</a> </p></td></tr><tr><td class="confluenceTd"><p><strong> </strong>6.6.8 Statistical analysis plans</p></td><td class="confluenceTd"><p><strong> </strong>A clear description must be provided of the statistical tools, techniques,</p><p>analyses used in the design and conduct of clinical investigations, and analysis of clinical data within the overall clinical evaluation.</p></td><td class="confluenceTd"><p>Incomplete - need to add</p></td></tr><tr><td class="confluenceTd"><p>6.6.9 Copies of literature articles</p></td><td class="confluenceTd"><p>A copy of all literature articles selected and analysed within the clinical evaluation report should be included in the Technical Documentation.</p></td><td class="confluenceTd"><p>Incomplete</p></td></tr><tr><td class="confluenceTd"><p><strong> 6.6.10 Summary of Safety and Clinical Performance</strong></p></td><td class="confluenceTd"><p>For Class III and implantable devices other than custom-made or investigational devices, a Summary of Safety &amp; Clinical Performance (SSCP) per Article 32 must be provided in the Technical Documentation.</p><p>·     The SSCP should be written clearly and understandable to the intended user and patient (if relevant) and should contain all the elements listed in MDR Article 32, Sec 2.</p><p>·     Please consult current available guidance for SSCP content and format as per MDCG 2019-9.</p><p>·     A draft SSCP in English is acceptable at the time of initial submission.</p><p>·     Once the SSCP has been finalised based on BSI review, Manufacturers should submit the final version of the English SSCP, which is in pdf format and is printable, searchable before a certificate recommendation can be made.</p><p>·     The SSCP should be updated annually (as per Article 61), if indicated, over the lifetime of the device as needed, and updates should be defined in the Post-Market Surveillance Plan.</p><p>For Class IIa implantable and Class IIb implantable WET (Well-Established Technologies) devices, MDR allows NBs to choose representative devices from each device category or generic device group respectively for the assessment of Technical Documentation. The SSCPs for such devices chosen as the representative samples will be validated by the NB as part of the Technical Documentation assessment for those devices. The MDCG document 2019-9 requires that NBs also upload the <u>unvalidated</u> SSCPs of the devices that were not chosen as representative devices (but are part of the same device categories or generic device groups) to EUDAMED. Hence Manufacturers may submit these unvalidated SSCPs at any time during the certification process to BSI, but before a BSI Scheme Manager prepares and makes a recommendation for certification based on the completion of all the required conformity assessments (including Technical Documentation assessment) for the relevant device categories or generic device groups.</p><p>(The MDCG guidance on SSCPs, MDCG 2019-9, also includes several requirements related to languages, translations of SSCPs depending on the Member State requirements related to languages and the availability of translated SSCPs on EUDAMED prior to placing affected devices on the market within these Member States. Manufacturer’s processes/procedures related to making the translated SSCPs available to BSI (for the NB to upload these to EUDAMED) and ensuring that they are available on EUDAMED prior to placing the devices on the market within these Member States will be audited as part of the BSI QMS audits)</p></td><td class="confluenceTd"><p>See <a href="OV-G1.3-Summary-of-Safety-and-Clinical-Performance-ONAVITAL_80117761.html" data-linked-resource-id="80117761" data-linked-resource-version="12" data-linked-resource-type="page">OV G1.3 Summary of Safety and Clinical Performance ONAVITAL</a> </p><p>Complete</p></td></tr><tr><td data-highlight-colour="#b3f5ff" colspan="3" class="confluenceTd"><p><strong>6.7 Post-market surveillance</strong></p></td></tr><tr><td class="confluenceTd"><p><strong> </strong></p><p><strong>6.7.1 Post Market Surveillance data (Market History, worldwide and EU sales volumes, Complaints data and trend analyses; Vigilance data and trend analyses; data from other PMS sources)</strong></p></td><td class="confluenceTd"><p>Please provide sales, complaints and vigilance data for the last 5 years for your device,</p><p>·     Sales and complaints data should include sales outside of the EU. A breakdown should be provided to enable evaluation of sales and complaints by region.</p><p>·     Complaints data should be evaluated rather than just listed. For example, why is the complaints rate considered acceptable? Have any trends been analysed and noted, or corrective actions taken? What is the status of these actions? Has a comparison of PMS data been made to the expected occurrence in the risk assessment? Full details of vigilance issues should be provided, including the status of any Field Safety Corrective Actions or Notices, the associated CAPAs and patient outcomes. This data should include FSCA or FSN outside the EU, if related to a device which is sold in the EU.</p><p>·     Ensure that the PMS data submitted at the time of the submission is up to date.</p></td><td class="confluenceTd"><p>See  <a href="OV-G2.1.-Post-Market-Surveillance-Plan_3343062.html" data-linked-resource-id="3343062" data-linked-resource-version="11" data-linked-resource-type="page">OV G2.1. Post-Market Surveillance Plan</a>  </p></td></tr><tr><td class="confluenceTd"><p><strong> </strong></p><p><strong>6.7.2 Post market surveillance plan</strong></p></td><td class="confluenceTd"><p>A Post-Market Surveillance Plan (PMS Plan) commensurate with the product risk, lifetime, and available clinical data should be provided for each device / device family.</p><p>·     Ensure that the PMS plan adequately justifies the monitoring of the safety and intended performance of the device.</p><p>·     If Post-Market Clinical Follow-up (PMCF) is not part of the PMS Plan, please ensure that adequate justification is provided, based on the risk and clinical data available for the device.</p><p>·     A copy of the Post Market Surveillance procedure should also be provided. Please note that the procedure is not the same as the Plan – the former refers to the manufacturer’s quality system requirements and is generic to all devices marketed by a manufacturer, whereas the latter is specific to the subject device, and can only be generated in light of data from the clinical evaluation and risk evaluation for that device.</p></td><td class="confluenceTd"><p>See <a href="OV-G2.1.-Post-Market-Surveillance-Plan_3343062.html" data-linked-resource-id="3343062" data-linked-resource-version="11" data-linked-resource-type="page">OV G2.1. Post-Market Surveillance Plan</a> </p><p>Complete</p></td></tr><tr><td class="confluenceTd"><p><strong> </strong></p><p><strong>6.7.3 Periodic Safety Update Reports (if available)</strong></p></td><td class="confluenceTd"><p><strong> </strong></p><p>For Class III, IIb, and IIa devices, manufacturers must prepare a periodic safety update report (“PSUR”) for each device or group of devices summarising results and conclusions of post-market surveillance data analysis as a result of the PMS plan described above. The PSUR should contain all the elements outlined in MDR Article 86 and any applicable MDCG guidance documents. Any PSURs the manufacturers may have</p><p>issued by the time of submission must be included.</p></td><td class="confluenceTd"><p>None produced as yet as device not yet on market.</p></td></tr><tr><td class="confluenceTd"><p><strong> </strong></p><p><strong>6.7.4 Post market clinical follow-up plan &amp; protocols</strong></p></td><td class="confluenceTd"><p>Please provide a PMCF plan including all necessary elements outlined per Part B of MDR Annex XIV and any applicable MDCG guidance documents.</p><p><strong> </strong></p><p>If the PMCF plan includes a PMCF study, include the study protocol.</p></td><td class="confluenceTd"><p>See <a href="OV-G2.2.-Post-Market-Clinical-Follow-Up-Plan_80150529.html" data-linked-resource-id="80150529" data-linked-resource-version="9" data-linked-resource-type="page">OV G2.2. Post-Market Clinical Follow Up Plan</a> </p><p /></td></tr><tr><td class="confluenceTd"><p><strong> </strong></p><p><strong>6.7.5 Post market clinical follow-up reports</strong></p></td><td class="confluenceTd"><p>Include any information and reports from PMCF activities previously carried out.</p><p><strong> </strong></p><p>This should clearly identify the PMCF study, which products are included and the applicable indication of use. In cases with multiple products and studies a table is preferable.</p><p><strong> </strong></p><p>The Notified Body may be required to periodically review results from</p><p>ongoing or completed PMCF studies following CE mark certification, including a specialised clinical evaluator in some cases.</p></td><td class="confluenceTd"><p>None produced as yet as device not yet on market.</p></td></tr></tbody></table></div><p /><h3 id="OVPartG:ClinicalEvaluation,PMSandPMCF-3.DocumentDistribution">3. Document Distribution</h3><div class="table-wrap"><table data-table-width="760" data-layout="default" data-local-id="e5988672-ffc0-4732-9daf-ca0c38be5c42" class="confluenceTable"><colgroup><col style="width: 380.0px;"/><col style="width: 380.0px;"/></colgroup><tbody><tr><td class="confluenceTd"><p> </p></td><td class="confluenceTd"><p>Action/ information</p></td></tr><tr><td class="confluenceTd"><p>This document is intended for an internal and (restricted) external audience.</p><p>All external distribution of this document must be approved prior to circulation.</p></td><td class="confluenceTd"><p>Information</p><p> </p></td></tr></tbody></table></div><p> </p>
                    </div>

                    
                                                      
                </div>             </div> 
            <div id="footer" role="contentinfo">
                <section class="footer-body">
                    <p>Document generated by Confluence on Jun 30, 2025 16:10</p>
                    <div id="footer-logo"><a href="http://www.atlassian.com/">Atlassian</a></div>
                </section>
            </div>
        </div>     </body>
</html>
